Protective role of ginsenoside Rg1 in the dynamic progression of liver injury to fibrosis: a preclinical meta-analysis
BackgroundThe pathological progression from liver injury to fibrosis is a hallmark of liver disease, with no effective strategies to halt this transition. Ginsenoside Rg1 has demonstrated a range of hepatoprotective properties; however, systematic preclinical evidence supporting its therapeutic pote...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1512184/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832583773799055360 |
|---|---|
| author | Lijuan Dan Xiuyan Li Shuanglan Chen Xiaojie You Dong Wang Tianyuan Wang Jia Li Wenping Liu Jie Mu Quansheng Feng Quansheng Feng |
| author_facet | Lijuan Dan Xiuyan Li Shuanglan Chen Xiaojie You Dong Wang Tianyuan Wang Jia Li Wenping Liu Jie Mu Quansheng Feng Quansheng Feng |
| author_sort | Lijuan Dan |
| collection | DOAJ |
| description | BackgroundThe pathological progression from liver injury to fibrosis is a hallmark of liver disease, with no effective strategies to halt this transition. Ginsenoside Rg1 has demonstrated a range of hepatoprotective properties; however, systematic preclinical evidence supporting its therapeutic potential for liver injury and fibrosis remains limited. Purpose. This study evaluated the efficacy and underlying mechanisms of ginsenoside Rg1 in animal models of liver injury and fibrosis, and providing a basis for future clinical investigation.MethodsA systematic review was conducted on preclinical studies published in PubMed, Web of Science, and Embase databases up to 1 August 2024, adhereing to rigorous quality standards. The methodological quality was assessed using SYRCLE’s risk of bias tool. Meta-analysis and subgroup analysis were performed using Revman 5.4 software, while publication bias was evaluated through funnel plots and Egger’s test in STATA 15.0 software. Additionally, a time-dose interval curve was utilized to assess the dose-response relationship and identify the effective dose of ginsenoside Rg1 for treating liver injury and fibrosis.ResultsTwenty-four trials involving 423 animals were included. The findings indicated that ginsenoside Rg1 significantly improved liver function markers (ALT and AST), reduced pathological indicators associated with liver injury and fibrosis, and lowered liver fibrosis-related markers (α-SMA, HYP, and PCIII). Furthermore, it exhibited beneficial effects on mechanistic indicators of inflammation, oxidative stress, and apoptosis, compared to the control group (P < 0.05). Time-dose interval analysis revealed that the effective dose range of ginsenoside Rg1 was between 4 and 800 mg/kg/d.ConclusionRg1 at a dose of 4–800 mg/kg/d mitigates the progression of liver injury to fibrosis via anti-inflammatory, antioxidative, and anti-apoptotic pathways.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD 42024557878. |
| format | Article |
| id | doaj-art-43cff598245144488f9800e5e217b927 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-43cff598245144488f9800e5e217b9272025-01-28T06:41:06ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011610.3389/fphar.2025.15121841512184Protective role of ginsenoside Rg1 in the dynamic progression of liver injury to fibrosis: a preclinical meta-analysisLijuan Dan0Xiuyan Li1Shuanglan Chen2Xiaojie You3Dong Wang4Tianyuan Wang5Jia Li6Wenping Liu7Jie Mu8Quansheng Feng9Quansheng Feng10School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaSchool of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaTraditional Chinese Medicine Department, 363 Hospital of Chengdu, Chengdu, ChinaTCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaSchool of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaBackgroundThe pathological progression from liver injury to fibrosis is a hallmark of liver disease, with no effective strategies to halt this transition. Ginsenoside Rg1 has demonstrated a range of hepatoprotective properties; however, systematic preclinical evidence supporting its therapeutic potential for liver injury and fibrosis remains limited. Purpose. This study evaluated the efficacy and underlying mechanisms of ginsenoside Rg1 in animal models of liver injury and fibrosis, and providing a basis for future clinical investigation.MethodsA systematic review was conducted on preclinical studies published in PubMed, Web of Science, and Embase databases up to 1 August 2024, adhereing to rigorous quality standards. The methodological quality was assessed using SYRCLE’s risk of bias tool. Meta-analysis and subgroup analysis were performed using Revman 5.4 software, while publication bias was evaluated through funnel plots and Egger’s test in STATA 15.0 software. Additionally, a time-dose interval curve was utilized to assess the dose-response relationship and identify the effective dose of ginsenoside Rg1 for treating liver injury and fibrosis.ResultsTwenty-four trials involving 423 animals were included. The findings indicated that ginsenoside Rg1 significantly improved liver function markers (ALT and AST), reduced pathological indicators associated with liver injury and fibrosis, and lowered liver fibrosis-related markers (α-SMA, HYP, and PCIII). Furthermore, it exhibited beneficial effects on mechanistic indicators of inflammation, oxidative stress, and apoptosis, compared to the control group (P < 0.05). Time-dose interval analysis revealed that the effective dose range of ginsenoside Rg1 was between 4 and 800 mg/kg/d.ConclusionRg1 at a dose of 4–800 mg/kg/d mitigates the progression of liver injury to fibrosis via anti-inflammatory, antioxidative, and anti-apoptotic pathways.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD 42024557878.https://www.frontiersin.org/articles/10.3389/fphar.2025.1512184/fullginsenoside Rg1liver injuryliver fibrosispreclinical evidencemeta-analysis |
| spellingShingle | Lijuan Dan Xiuyan Li Shuanglan Chen Xiaojie You Dong Wang Tianyuan Wang Jia Li Wenping Liu Jie Mu Quansheng Feng Quansheng Feng Protective role of ginsenoside Rg1 in the dynamic progression of liver injury to fibrosis: a preclinical meta-analysis Frontiers in Pharmacology ginsenoside Rg1 liver injury liver fibrosis preclinical evidence meta-analysis |
| title | Protective role of ginsenoside Rg1 in the dynamic progression of liver injury to fibrosis: a preclinical meta-analysis |
| title_full | Protective role of ginsenoside Rg1 in the dynamic progression of liver injury to fibrosis: a preclinical meta-analysis |
| title_fullStr | Protective role of ginsenoside Rg1 in the dynamic progression of liver injury to fibrosis: a preclinical meta-analysis |
| title_full_unstemmed | Protective role of ginsenoside Rg1 in the dynamic progression of liver injury to fibrosis: a preclinical meta-analysis |
| title_short | Protective role of ginsenoside Rg1 in the dynamic progression of liver injury to fibrosis: a preclinical meta-analysis |
| title_sort | protective role of ginsenoside rg1 in the dynamic progression of liver injury to fibrosis a preclinical meta analysis |
| topic | ginsenoside Rg1 liver injury liver fibrosis preclinical evidence meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1512184/full |
| work_keys_str_mv | AT lijuandan protectiveroleofginsenosiderg1inthedynamicprogressionofliverinjurytofibrosisapreclinicalmetaanalysis AT xiuyanli protectiveroleofginsenosiderg1inthedynamicprogressionofliverinjurytofibrosisapreclinicalmetaanalysis AT shuanglanchen protectiveroleofginsenosiderg1inthedynamicprogressionofliverinjurytofibrosisapreclinicalmetaanalysis AT xiaojieyou protectiveroleofginsenosiderg1inthedynamicprogressionofliverinjurytofibrosisapreclinicalmetaanalysis AT dongwang protectiveroleofginsenosiderg1inthedynamicprogressionofliverinjurytofibrosisapreclinicalmetaanalysis AT tianyuanwang protectiveroleofginsenosiderg1inthedynamicprogressionofliverinjurytofibrosisapreclinicalmetaanalysis AT jiali protectiveroleofginsenosiderg1inthedynamicprogressionofliverinjurytofibrosisapreclinicalmetaanalysis AT wenpingliu protectiveroleofginsenosiderg1inthedynamicprogressionofliverinjurytofibrosisapreclinicalmetaanalysis AT jiemu protectiveroleofginsenosiderg1inthedynamicprogressionofliverinjurytofibrosisapreclinicalmetaanalysis AT quanshengfeng protectiveroleofginsenosiderg1inthedynamicprogressionofliverinjurytofibrosisapreclinicalmetaanalysis AT quanshengfeng protectiveroleofginsenosiderg1inthedynamicprogressionofliverinjurytofibrosisapreclinicalmetaanalysis |